Is Taisho Pharmaceutical profitable?

Yes. For the fiscal year ended March 31, 2025, the operating company Taisho Pharmaceutical Co., Ltd. reported revenue of ¥196.96 billion, operating profit of ¥31.18 billion, and net income of ¥34.79 billion, with an equity ratio around 84.8%.

Is Taisho Pharmaceutical still publicly traded?

No. Following a management buyout led by the founding Uehara family at ¥8,620 per share announced November 26, 2023, Taisho delisted from the Tokyo Stock Exchange on April 9, 2024, and is now fully privately held.

Who owns Taisho Pharmaceutical now?

The founding Uehara family controls Taisho via a vehicle originally named Otemon Co., Ltd., which merged with the old holding company and renamed itself Taisho Pharmaceutical Holdings Co., Ltd. on July 1, 2024, with Shigeru Uehara as CEO.

Could AI replace Taisho Pharmaceutical's business?

Unlikely for core operations. Taisho's regulated manufacturing, retail pharmacy distribution, and century-old brands like Lipovitan D and Pabron are not AI-replaceable; AI's role is limited to early drug discovery, seen in its 2020 partnership with Insilico Medicine on anti-aging drug research.

Who is Taisho Pharmaceutical's biggest competitor?

Domestically it competes with Rohto Pharmaceutical, Kobayashi Pharmaceutical, Lion Corp, SS Pharmaceutical, and Daiichi Sankyo Healthcare in Japan's OTC market; globally, Haleon, Bayer Consumer Health, Reckitt Benckiser, J&J, and P&G are the multinational category leaders it has long fended off from Japan.

Is there legal risk from Taisho's 2024 management buyout?

Yes. Minority shareholders Curi RMB Capital and Oasis Management pursued Tokyo District Court action starting around February 20, 2024, arguing the ¥8,620/share MBO price was below book value; Kaname Capital also considered damages suits.

Pharma and healthcare groups · Japan

Taisho Pharmaceutical

taisho.co.jp ↗

Japan's top over the counter drugmaker, maker of Lipovitan D and Pabron.

Hard to displace

Assessed 25 July 2026 · Evidence as of 25 July 2026

Strong structural protection; the business model survives ai pressure.

On the recordSince 25 July 2026 · Checkable from May 2026 · Every call on the record Checkpoint: FY ended March 2026 financial results disclosure

The call

A debt free, century old OTC leader shielded by regulation and pharmacy ties, now privately held and facing minority shareholder litigation over its buyout price.

Taisho Pharmaceutical makes common medicines you buy without a prescription in Japan, like Lipovitan D energy drink and Pabron cold medicine. It is hard to replace because Japanese pharmacies trust its century-old brands, the government makes it expensive to enter the market with new drugs, and making medicine requires real factories and real inspections that AI cannot do. The one thing that could change the picture is whether Taisho uses its massive cash pile to buy drugmakers overseas, or whether it finds new customers in other countries instead of selling only in Japan where the population is shrinking.

Why

AI pressure: None apparent. AI chatbots can suggest generic remedies but cannot dispense drugs or replace pharmacy shelf space in Japan. Could AI do the core job? Unlikely.

Bigger players: Haleon (GSK consumer health spinoff). Global OTC majors like Haleon, Bayer, and Reckitt could push harder into Japan through a distribution partner, but none has moved yet. Could a giant copy it? No, they are blocked.

What protects it. Japan's drug approval rules, entrenched pharmacy relationships, and a century of brand trust in Lipovitan D and Pabron keep foreign rivals out.

What would change this call

Taisho's FY ended March 2026 financial results, once disclosed, show revenue up, flat, or down versus FY2025's ¥196.96 billion. Confirms whether the post-MBO revenue slide has stabilized or is still declining.
Tokyo District Court ruling or settlement in the Curi RMB, Oasis, and Kaname suits contesting the MBO price. Shows whether the buyout price is judged fair or forces a payout that dents the balance sheet.
Announcement of a large overseas acquisition funded from Taisho's net-cash pile (a 'third UPSA or DHG' deal). Would test whether management is over-extending the debt-free balance sheet for growth.

Key numbers

Revenue Y196.96 billion, FY ended March 2025 (2025-03-31)
Operating profit Y31.18 billion, FY ended March 2025 (2025-03-31)
Net assets Y439.4 billion, equity ratio ~85% (2025-03-31)

Named risks

Tokyo District Court litigation from Curi RMB, Oasis, Kaname over MBO price starting Feb 2024. Severity: medium
Financial disclosure now limited to Japanese kessan koukoku after delisting, reducing transparency. Severity: medium
Active brand pruning (Coppertone discontinued Sept 2024, Vicks rights transferred Sept 2025) may shrink revenue. Severity: medium
Speculated large debt-funded overseas acquisition could overextend an otherwise debt-free balance sheet. Severity: medium
July 2026 fraud/impersonation warning suggests active scam campaign targeting the company or customers. Severity: low

Rivals, as read in July 2026

Rival	Direction	Evidence
Rohto Pharmaceutical	contesting	Domestic OTC rival in stable oligopoly, no share shift reported as of 2026
Kobayashi Pharmaceutical	contesting	Domestic OTC peer competing across similar drugstore channels
Lion Corp	contesting	Different product mix but overlapping OTC categories in Japan
Haleon	contesting	Global OTC major has tried Japan for decades without displacing Taisho, per historical pattern
Procter & Gamble	contesting	Multinational consumer health incumbent, no measurable Japan share gain against Taisho reported
Reckitt Benckiser	contesting	Global OTC competitor, no reported Japan distribution breakthrough as of mid-2026

Questions people ask

Is Taisho Pharmaceutical profitable?: Yes. For the fiscal year ended March 31, 2025, the operating company Taisho Pharmaceutical Co., Ltd. reported revenue of ¥196.96 billion, operating profit of ¥31.18 billion, and net income of ¥34.79 billion, with an equity ratio around 84.8%.
Is Taisho Pharmaceutical still publicly traded?: No. Following a management buyout led by the founding Uehara family at ¥8,620 per share announced November 26, 2023, Taisho delisted from the Tokyo Stock Exchange on April 9, 2024, and is now fully privately held.
Who owns Taisho Pharmaceutical now?: The founding Uehara family controls Taisho via a vehicle originally named Otemon Co., Ltd., which merged with the old holding company and renamed itself Taisho Pharmaceutical Holdings Co., Ltd. on July 1, 2024, with Shigeru Uehara as CEO.
Could AI replace Taisho Pharmaceutical's business?: Unlikely for core operations. Taisho's regulated manufacturing, retail pharmacy distribution, and century-old brands like Lipovitan D and Pabron are not AI-replaceable; AI's role is limited to early drug discovery, seen in its 2020 partnership with Insilico Medicine on anti-aging drug research.
Who is Taisho Pharmaceutical's biggest competitor?: Domestically it competes with Rohto Pharmaceutical, Kobayashi Pharmaceutical, Lion Corp, SS Pharmaceutical, and Daiichi Sankyo Healthcare in Japan's OTC market; globally, Haleon, Bayer Consumer Health, Reckitt Benckiser, J&J, and P&G are the multinational category leaders it has long fended off from Japan.
Is there legal risk from Taisho's 2024 management buyout?: Yes. Minority shareholders Curi RMB Capital and Oasis Management pursued Tokyo District Court action starting around February 20, 2024, arguing the ¥8,620/share MBO price was below book value; Kaname Capital also considered damages suits.

Timeline

2026-07-07Taisho issues public warning about fraudulent messages impersonating the company
2026-04Launches energy jelly product Lipovitan Jelly Performance
2026-03Launches OTC sleep aid Lipovitan Yorurizumu
2025-11Launches prescription insomnia drug Volzi
2025-09-30Transfers Vicks VapoRub manufacturing/marketing rights to Astena Holdings
2025-03-31FY2025 results: revenue ¥196.96B, operating profit ¥31.18B, net income ¥34.79B
2024-07-01Otemon Co. renamed Taisho Pharmaceutical Holdings; Shigeru Uehara becomes CEO
2024-04-09Taisho delists from the Tokyo Stock Exchange
2024-03Launches Alli, Japan's first direct-OTC visceral-fat-reduction drug
2023-11-26Uehara family launches MBO tender offer at ¥8,620/share, ~55% premium

Revision history

25 July 2026

First assessed. Hard to displace. The text above is fixed as of this date and is not edited afterwards.

In the same band

Vertex Pharmaceuticals Tenet Healthcare Intuitive Surgical

More in Pharma and healthcare groups →

Sources